Loading Events

Upcoming Events

Events Search and Views Navigation

Event Views Navigation

September 2019

AES Seed Grant Program 

September 22
|Recurring Event (See all)

One event on March 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: September 22, 2019 or March 23, 2020
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

October 2019

Cycle 3: Whitehall Foundation Grants-in-Aids

October 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award:  Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Cycle 3: Whitehall Foundation Research Grants

October 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

AES Research and Training Workshops

October 1
|Recurring Event (See all)

One event on October 1, 2019 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: April 15, 2019 or October 1, 2019
Award: AES welcomes applications for funding to support scientific conferences and workshops focused on epilepsy research and training. Applications for workshop funding are reviewed by the AES Research and Training Council, and the number and amount of awards made each year are contingent on available funds.

Find out more »

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer’s disease and Alzheimer’s related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)

October 9

Sponsor: NIH
LOI Due Date: September 9, 2019
Application Deadline: October 9, 2019
Description:The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Award: Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

Find out more »

Cycle 4: Alzheimer’s Drug Discovery Foundation

October 11

LOI DUE OCTOBER 11, 2019
Drug Discovery Program
The Drug Discovery RFP supports novel drug programs and repurposed/repositioned programs. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

NIH R21, R03

October 16
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

Society for Neuroscience Annual Meeting 2019

October 19 - October 23

SfN’s 49th annual meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers, explore new tools and technologies, and advance careers. Join 30,000 colleagues from more than 80 countries at the world’s largest marketplace of ideas and tools for global neuroscience.

Find out more »

Exploring Human Host-Microbiome Interaction in Health and Disease

October 23 - October 25
Wellcome Genome Campus, Hinxton, Saffron Walden, CB10 1SA United Kingdom

The 8th Exploring Human Host-Microbiome Interactions in Health and Disease meeting will once again bring together leading scientists and clinicians from the fields of microbiology, gastroenterology, neuroscience, cancer and public health to discuss the latest developments in this fast-moving area.

Find out more »

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

October 28

Sponsor: NIH Common Fund Program
LOI Due Date: September 28, 2019
Application Deadline: October 28, 2019
Details: The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Award:  Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.

Find out more »

November 2019

American Fellowships: Summer/Short-Term Research Publication Grants

November 1

Sponsor: American Association of University Women Educational Foundation
Due Date: November 1, 2019
Award: $6,000 is available for an eight-week grant period.

Find out more »

Cycle 3: Prevention Research in Mid-Life Adults (R01)

November 5

Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.

Find out more »

NIH Cycles R01 and U01

November 5
|Recurring Event (See all)

One event on March 5, 2019 at 12:00 am

One event on November 5, 2019 at 12:00 am

NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.

 

Find out more »

December 2019

48th Annual AANS/CNS Section on Pediatric Neurological Surgery Meeting

December 5 - December 8
Hyatt Gainey Ranch, 7500 E Doubletree Ranch Rd
Scottsdale, AZ 85258 United States

This year’s speakers at the Annual AANS/CNS Section on Pediatric Neurosurgery meeting include well-known experts who will present their unique, relevant and fascinating knowledge of their respective industries.

 

Find out more »

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

January 2020

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

January 1, 2020

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years

Find out more »

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Healthcare Research by Community Physicians

January 1, 2020

Sponsor: Physicans’ Services Incorporated Foundation

Due Date: Applications accepted on a rolling basis

Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.

 

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5, 2020

DUE DATE: JANUARY 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »
+ Export Events